Overview

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Diseas

Status:
Completed

Trial end date:
2019-11-13

Target enrollment:

Participant gender:

Summary

Assess the safety and tumor response of utilizing an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine given in combination with standard of care (SoC) checkpoint inhibitors (CPI) in patients with stage IV melanoma with measurable disease.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Cancer Insight, LLC

Collaborator:

Elios Therapeutics, LLC

Treatments:

Vaccines